Exploring synergy between classic mutagens and antibiotics to examine mechanisms of synergy and antibiotic action

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1515-1520

  Song, Lisa Yun ^a,b   D'Souza, Sara ^a,b   Lam, Karen ^a,b   Kang, Tina Manzhu ^a,b   Yeh, Pamela ^a   Miller, Jeffrey H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOPURINE; 4 NITROQUINOLINE 1 OXIDE; ANTIBIOTIC AGENT; AZACITIDINE; BROXURIDINE; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; MUTAGENIC AGENT; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN; ZEBULARINE; ANTIINFECTIVE AGENT; CYTIDINE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; DRUG POTENTIATION; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

2-AMINOPURINE; 4-NITROQUINOLINE-1-OXIDE; ANTI-BACTERIAL AGENTS; AZACITIDINE; BROMODEOXYURIDINE; CHLORAMPHENICOL; CIPROFLOXACIN; CYTIDINE; DNA BREAKS, DOUBLE-STRANDED; DRUG SYNERGISM; ERYTHROMYCIN; ESCHERICHIA COLI; GENTAMICINS; MICROBIAL SENSITIVITY TESTS; MUTAGENS; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

EID: 84960157320     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02485-15     Document Type: Article

References (33)

1. Alekshun MN, Levy SB. 2007. Molecular mechanisms of antibacterial multidrug resistance. Cell 128:1037-1050. http://dx.doi.org/10.1016/j.cell.2007.03.004.
2. Davies J. 2007. Microbes have the last word. A drastic re-evaluation of antimicrobial treatment is needed to overcome the threat of antibioticresistant bacteria. EMBO Rep 8:616-821. http://dx.doi.org/10.1038/sj.embor.7401022.
3. Yeh P, Tschumi AI, Kishony R. 2006. Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38:489-494. http://dx.doi.org/10.1038/ng1755.
4. Giamarellou H. 1986. Aminoglycosides plus beta-lactams against Gramnegative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 80:126-137.
5. Zhou A, Kang TM, Yuan J, Beppler C, Nguyen C, Mao Z, Nquyen NQ, Yeh P, Miller JH. 2015. Synergistic interactions of vancomycin with different antibiotics againstEscherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E.coli. Antimicrob Agents Chemother 59:276-281. http://dx.doi.org/10.1128/AAC.03502-14.
6. Lockhardt SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. 2007. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 45:3352-3359.
7. Nikaido H. 1989. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 33:1831-1836. http://dx.doi.org/10.1128/AAC.33.11.1831.
8. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. http://dx.doi.org/10.1016/j.cell.2007.06.049.
9. Foti JJ, Devadoss B, Winkler JA, Collins JA, Walker GC. 2012. Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. Science 336:315-319. http://dx.doi.org/10.1126/science.1219192.
10. Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, Takahashi N, Chan CT, Lobritz MA, Braff D, Schwarz EG, Ye JD, Pati M, Vercruysse M, Ralifo PS, Allison KR, Kalil AS, Ting AY, Walker GC, Collins JJ. 2014. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc Natl Acad Sci U S A 111:E2100-E2109. http://dx.doi.org/10.1073/pnas.1321343111.
11. Belenky P, Ye JD, Porter CB, Cohen NR, Lobritz MA, Ferrante T, Jain S, Korry BJ, Schwarz EG, Walker GC, Collins JJ. 2015. Bactericidal antibiotics induce toxic metabolic perturbations that lead tocellular damage. Cell Rep 13:968-980. http://dx.doi.org/10.1016/j.celrep. 2015.09.059.
12. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coliK-12 in-frame single-gene knockout mutants: the Keio collection. Mol Syst Biol 2:2006.0008.
13. Miller JH. 1992. A short course in bacterial genetics: a laboratory manual and handbook for Escherichia coli and related bacteria. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
14. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
15. Nagao M, Sugimura T. 1976. Molecular biology of the carcinogen, 4-nitroquinoline 1-oxide. Adv Cancer Res 23:131-169. http://dx.doi.org/10.1016/S0065-230X (08) 60545-X.
16. Arima Y, Nishigori C, Takeuchi T, Oka S, Morimoto K, Utani A, Myachi Y. 2006. 4-Nitroquinoline 1-oxide forms 8-hydroxydeoxyguanosine in human fibroblasts through reactive oxygen species. Toxicol Sci 91:382-392. http://dx.doi.org/10.1093/toxsci/kfj161.
17. Marquez V, Barchi JJ, Jr, Kelly JA, Rao KV, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA. 2005. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids 24:305-318. http://dx.doi.org/10.1081/NCN-200059765.
18. Betham B, Salhout S, Marquez VE, Bhagwat AS. 2010. Use of Drosophila deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of deoxycytidine analogs in Escherichia coli. DNA Repair (Amst) 9:153-160. http://dx.doi.org/10.1016/j.dnarep. 2009.11.006.
19. Kuo HK, Griffith JD, Kreuzer KN. 2007. 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res 67:8248-8254. http://dx.doi.org/10.1158/0008-5472. CAN-07-1038.
20. Lal D, Som S, Friedman S. 1988. Survival and mutagenic effects of 5-azacytidine in Escherichia coli. Mutat Res 193:229-236.
21. Bhagwat AS, Roberts RJ. 1987. Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12. J Bacteriol 169:537-546.
22. Barbé J, Gilbert R, Guerrero R. 1986. 5-Azacytidine survival and induction of the SOS response in Escherichia coli K-12. Mutat Res 166:9-16.
23. Glickman B, van den Elsen P, Radman M. 1978. Induced mutagenesis in mutants of Escherichia coli: a role for 6-methyladenine residues in mutation avoidance. Mol Gen Genet 163:307-312. http://dx.doi.org/10.1007/BF00271960.
24. Becket E, Chen F, Tamae C, Miller JH. 2010. Determination of hypersensitivitytogenotoxic agents amongEscherichia colisingle gene knockout mutants. DNA Repair 9:949-957. http://dx.doi.org/10.1016/j.dnarep. 2010.06.008.
25. Becket E, Tse L, Yung M, Cosico A, Miller JH. 2012. Polynucleotide phosphorylase plays an important role in the generation of spontaneous mutations in Escherichia coli. J Bacteriol 194:5613-5620. http://dx.doi.org/10.1128/JB.00962-12.
26. Loewe S. 1953. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285-290.
27. Bushby SRM, Hitchings GH. 1968. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol 33:72-90.
28. Dar ME, Jorgensen TJ. 1995. Deletions at short direct repeats and base substitutions are characteristic mutations for bleomycin-induced doubleand single-strand breaks, respectively, in a human shuttle vector system. Nucleic Acids Res 23:3224-3230.
29. Garibyan L, Huang T, Kim M, Wolff E, Nguyen A, Nguyen T, Diep A, Hu K, Iverson A, Yang H, Miller JH. 2003. Use of the rpoB gene to determine the specificity of base substitutions on the Escherichia coli chromosome. DNA Repair 2:593-608. http://dx.doi.org/10.1016/S1568-7864 (03) 00024-7.
30. Curigliano G, Spitaleri G, Magni E, Lorizzo K, De Cobelli O, Locatelli M, Fumagalli L, Adamoil L, Cossu Rocca M, Verri E, De Pas T, Jereczek-Fossa B, Martinelli G, Goldhirsch A, Nole F. 2009. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. J Chemother 21:687-692. http://dx.doi.org/10.1179/joc.2009.21.6.687.
31. Rosenberg B. 1999. Platinum complexes for the treatment of cancer: why the search goes on, p 1-27. In Lippert B (ed), Chemistry and biochemistry of a leading anticancer drug. Wiley-VCH, New York, NY.
32. Yoo CB, Jones PA. 2006. Epigenetic therapy of cancer: past, present, and future. Nat Rev Drug Discov 5:37-50. http://dx.doi.org/10.1038/nrd1930.
33. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, De Coteau JF. 2007. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK-4B demethylation and reexpression. Exp Hematol 35:263-273. http://dx.doi.org/10.1016/j.exphem.2006.10.005.